These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 35182296)

  • 1. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
    Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
    MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
    Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of T-cell engagers for the treatment of follicular lymphoma.
    Rivas-Delgado A; Landego I; Falchi L
    Oncoimmunology; 2024; 13(1):2412869. PubMed ID: 39398477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab.
    Nägele V; Zugmaier G; Goebeler ME; Viardot A; Bargou R; Kufer P; Klinger M
    Exp Hematol; 2021 Aug; 100():32-36. PubMed ID: 34228983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
    Bukhari A; Lee ST
    Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
    [No Abstract]   [Full Text] [Related]  

  • 14. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
    Larson SM; Walthers CM; Ji B; Ghafouri SN; Naparstek J; Trent J; Chen JM; Roshandell M; Harris C; Khericha M; Schweppe T; Berent-Maoz B; Gosliner SB; Almaktari A; Ceja MA; Allen-Auerbach MS; Said J; Nawaly K; Mead M; de Vos S; Young PA; Oliai C; Schiller GJ; Timmerman JM; Ribas A; Chen YY
    Cancer Discov; 2023 Mar; 13(3):580-597. PubMed ID: 36416874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models.
    Brinkmann BJ; Floerchinger A; Schniederjohann C; Roider T; Coelho M; Mack N; Bruch PM; Liebers N; Dötsch S; Busch DH; Schmitt M; Neumann F; Roessner PM; Seiffert M; Dietrich S
    Blood; 2024 Aug; 144(7):784-789. PubMed ID: 38805637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
    Chu Y; Gardenswartz A; Diorio C; Marks LJ; Lowe E; Teachey DT; Cairo MS
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101442. PubMed ID: 36907635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting non-Hodgkin lymphoma with blinatumomab.
    Sanders S; Stewart DA
    Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.